{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:47Z","timestamp":1792788107042,"version":"4.5.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi Genzyme Turkey"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This consensus statement by a panel of Fabry experts aimed to identify areas of consensus on conceptual, clinical and therapeutic aspects of Fabry disease (FD) and to provide guidance to healthcare providers on best practice in the management of pediatric and adult patients with FD. This consensus statement indicated the clinical heterogeneity of FD as well as a large number of pathogenic variants in the\n                    <jats:italic>GLA<\/jats:italic>\n                    gene, emphasizing a need for an individualized approach to patient care. The experts reached consensus on the critical role of a high index of suspicion in symptomatic patients and screening of certain at-risk groups to reveal timely and accurate diagnosis of FD along with an increased awareness of the treating physician about the different kinds of pathogenic variants and their clinical implications. The experts emphasized the crucial role of timely recognition of FD with minimal delay from symptom onset to definite diagnosis in better management of FD patients, given the likelihood of changing the disease\u2019s natural history, improving the patients\u2019 quality of life and the prognosis after enzyme replacement therapy (ERT) administered through a coordinated, multidisciplinary care approach. In this regard, this consensus document is expected to increase awareness among physicians about unique characteristics of FD to assist clinicians in recognizing FD with a well-established clinical suspicion consistent with pathogenic variants and gender-based heterogeneous clinical manifestations of FD and in translating this information into their clinical practice for best practice in the management of patients with FD.\n                  <\/jats:p>","DOI":"10.1186\/s13023-022-02215-x","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T06:03:14Z","timestamp":1646200994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-3118","authenticated-orcid":false,"given":"Fatih","family":"Ezgu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Alpsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerrin","family":"Bicik Bahcebasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Kasapcopur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis","family":"Palamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Onay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binnaz Handan","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Akif","family":"Topcuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omac","family":"Tufekcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2215_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"2215_CR2","doi-asserted-by":"crossref","first-page":"103702","DOI":"10.1016\/j.ejmg.2019.103702","volume":"62","author":"PM Elliott","year":"2019","unstructured":"Elliott PM, Germain DP, Hilz MJ, Spada M, Wanner C, Falissard B. Why systematic literature reviews in Fabry disease should include all published evidence. Eur J Med Genet. 2019;62:103702.","journal-title":"Eur J Med Genet."},{"key":"2215_CR3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ejim.2014.07.009","volume":"25","author":"D Concolino","year":"2014","unstructured":"Concolino D, Degennaro E, Parini R. Fabry Delphi working group; Fabry Delphi working group. Delphi consensus on the current clinical and therapeutic knowledge on Anderson\u2013Fabry disease. Eur J Intern Med. 2014;25:751\u20136.","journal-title":"Eur J Intern Med."},{"key":"2215_CR4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","volume":"112","author":"A Hag\u00e8ge","year":"2019","unstructured":"Hag\u00e8ge A, R\u00e9ant P, Habib G, Damy T, Barone-Rochette G, Soulat G, et al. Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis. 2019;112:278\u201387.","journal-title":"Arch Cardiovasc Dis"},{"key":"2215_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89:44\u201354.","journal-title":"Clin Genet"},{"key":"2215_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.rce.2018.09.017","volume":"219","author":"EJ Calder\u00f3n Sandubete","year":"2019","unstructured":"Calder\u00f3n Sandubete EJ, de la Blanca EBP, Alonso-Ortiz Del R\u00edo C, Santamar\u00eda Olmo R, L\u00f3pez Mendoza M, Barcos Mart\u00ednez M, et al. Spanish multidisciplinary clinical practice guidelines for Anderson\u2013Fabry Disease in Adults. I. Method and recommendations. Rev Clin Esp. 2019;219:200\u20137.","journal-title":"Rev Clin Esp."},{"key":"2215_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816685735","volume":"5","author":"MA Curiati","year":"2017","unstructured":"Curiati MA, Aranda CS, Kyosen SO, Varela P. The challenge of diagnosis and indication for treatment in Fabry disease. J Inborn Errors Metab Screen. 2017;5:1\u20137.","journal-title":"J Inborn Errors Metab Screen"},{"key":"2215_CR8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","volume":"28","author":"TR Hsu","year":"2018","unstructured":"Hsu TR, Niu DM. Fabry disease: review and experience during newborn screening. Trends Cardiovasc Med. 2018;28:274\u201381.","journal-title":"Trends Cardiovasc Med"},{"key":"2215_CR9","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"2215_CR10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","volume":"81","author":"O Lidove","year":"2012","unstructured":"Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al. Fabry disease \u201cthe new great imposter\u201d: results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet. 2012;81:571\u20137.","journal-title":"Clin Genet"},{"key":"2215_CR11","first-page":"353","volume":"49","author":"E Tuncbilek","year":"2007","unstructured":"Tuncbilek E, Ozguc M. Application of medical genetics in Turkey. Turk J Pediatr. 2007;49:353\u20139.","journal-title":"Turk J Pediatr"},{"key":"2215_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/2326409815613806","author":"PA Rozenfeld","year":"2015","unstructured":"Rozenfeld PA, Romina C, Bioc RC, Lic NR, Kisinovsky I. The continuous challenge of diagnosing patients with Fabry disease in Argentina: genotype, experiences, anecdotes, and new learnings. J Inborn Errors Metab Screen. 2015. https:\/\/doi.org\/10.1177\/2326409815613806.","journal-title":"J Inborn Errors Metab Screen."},{"key":"2215_CR13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148\u201353.","journal-title":"Mol Genet Metab"},{"key":"2215_CR14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.gene.2018.11.054","volume":"687","author":"S Koca","year":"2019","unstructured":"Koca S, Tumer L, Okur I, Erten Y, Bakkaloglu S, Biberoglu G, et al. High incidence of co-existing factors significantly modifying the phenotype in patients with Fabry disease. Gene. 2019;687:280\u20138.","journal-title":"Gene"},{"key":"2215_CR15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1744-9987.2012.01092.x","volume":"16","author":"S Kalkan Ucar","year":"2012","unstructured":"Kalkan Ucar S, Sozmen E, Duman S, Basci A, Coker M. Alpha-galactosidase A activity levels in Turkish male hemodialysis patients. Ther Apher Dial. 2012;16:560\u20135.","journal-title":"Ther Apher Dial"},{"key":"2215_CR16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gene.2013.05.050","volume":"527","author":"I Okur","year":"2013","unstructured":"Okur I, Ezgu F, Biberoglu G, Tumer L, Erten Y, Isitman M, et al. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation. Gene. 2013;527:42\u20137.","journal-title":"Gene"},{"key":"2215_CR17","doi-asserted-by":"crossref","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson\u2013Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLOS ONE. 2017;12:e0173358.","journal-title":"PLOS ONE."},{"key":"2215_CR18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R. Fabry disease. Pharmacol Ther. 2009;122:65\u201377.","journal-title":"Pharmacol Ther"},{"key":"2215_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ymgme.2018.08.014","volume":"125","author":"S K\u00f6rver","year":"2018","unstructured":"K\u00f6rver S, Vergouwe M, Hollak CEM, van Schaik IN, Langeveld M. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. Mol Genet Metab. 2018;125:205\u201316.","journal-title":"Mol Genet Metab"},{"key":"2215_CR20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","volume":"60","author":"EF Neufeld","year":"1991","unstructured":"Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem. 1991;60:257\u201380.","journal-title":"Annu Rev Biochem"},{"key":"2215_CR21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res. 2008;64:550\u20135.","journal-title":"Pediatr Res"},{"key":"2215_CR22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2008;93:112\u201328.","journal-title":"Mol Genet Metab"},{"key":"2215_CR23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91:284\u201393.","journal-title":"Kidney Int"},{"key":"2215_CR24","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transpl. 2009;24:2102\u201311.","journal-title":"Nephrol Dial Transpl"},{"key":"2215_CR25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769\u201375.","journal-title":"J Med Genet"},{"key":"2215_CR26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","volume":"103","author":"A Mehta","year":"2010","unstructured":"Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, et al. Fabry disease: a review of current management strategies. QJM. 2010;103:641\u201359.","journal-title":"QJM"},{"key":"2215_CR27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"2215_CR28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31\u201340.","journal-title":"Am J Hum Genet"},{"key":"2215_CR29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30:1397\u2013405.","journal-title":"Hum Mutat."},{"key":"2215_CR30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","volume":"30","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007;30:68\u201378.","journal-title":"J Inherit Metab Dis"},{"key":"2215_CR31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med. 2009;11:790\u20136.","journal-title":"Genet Med"},{"key":"2215_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"2215_CR33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28:1631\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"2215_CR34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","volume":"3","author":"CM Eng","year":"1997","unstructured":"Eng CM, Ashley GA, Burgert TS, Enriquez AL, D\u2019Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med. 1997;3:174\u201382.","journal-title":"Mol Med"},{"key":"2215_CR35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","volume":"2","author":"J Shabbeer","year":"2006","unstructured":"Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics. 2006;2:297\u2013309.","journal-title":"Hum Genomics"},{"key":"2215_CR36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124:189\u2013203.","journal-title":"Mol Genet Metab"},{"key":"2215_CR37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","volume":"126","author":"DP Germain","year":"2019","unstructured":"Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126:224\u201335.","journal-title":"Mol Genet Metab"},{"key":"2215_CR38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, et al. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet. 2006;43:347\u201352.","journal-title":"J Med Genet"},{"key":"2215_CR39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab"},{"key":"2215_CR40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000060194","volume":"136","author":"DP Germain","year":"2001","unstructured":"Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol. 2001;136:234\u201340.","journal-title":"Contrib Nephrol"},{"key":"2215_CR41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","volume":"257","author":"DP Germain","year":"1999","unstructured":"Germain DP, Poenaru L. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem Biophys Res Commun. 1999;257:708\u201313.","journal-title":"Biochem Biophys Res Commun"},{"key":"2215_CR42","doi-asserted-by":"crossref","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864:129437.","journal-title":"Biochim Biophys Acta Gen Subj."},{"key":"2215_CR43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","volume":"97","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M. Cardiac manifestations of Anderson\u2013Fabry disease in children and adolescents. Acta Paediatr. 2008;97:463\u20139.","journal-title":"Acta Paediatr"},{"key":"2215_CR44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","volume":"147","author":"MA Cabrera-Salazar","year":"2005","unstructured":"Cabrera-Salazar MA, O\u2019Rourke E, Charria-Ortiz G, Barranger JA. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr. 2005;147:102\u20135.","journal-title":"J Pediatr"},{"key":"2215_CR45","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics. 2005;115:e344\u201355.","journal-title":"Pediatrics"},{"key":"2215_CR46","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000001450","volume":"84","author":"M L\u00f6hle","year":"2015","unstructured":"L\u00f6hle M, Hughes D, Milligan A, Richfield L, Reichmann H, Mehta A, et al. Clinical prodromes of neurodegeneration in Anderson\u2013Fabry disease. Neurology. 2015;84:1454\u201364.","journal-title":"Neurology"},{"key":"2215_CR47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5606\/ArchRheumatol.2020.7135","volume":"35","author":"E Kiykim","year":"2020","unstructured":"Kiykim E, Sahin S, Zubarioglu T, Barut K, Adrovic A, Cansever MS, et al. Screening for Fabry disease in patients with juvenile systemic lupus erythematosus. Arch Rheumatol. 2020;35:7\u201312.","journal-title":"Arch Rheumatol"},{"key":"2215_CR48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s10528-016-9731-3","volume":"54","author":"C Huzmeli","year":"2016","unstructured":"Huzmeli C, Candan F, Alaygut D, Bagci G, Akkaya L, Bagci B, et al. Prevalence of Fabry disease in Familial mediterranean fever patients from central Anatolia of Turkey. Biochem Genet. 2016;54:448\u201356.","journal-title":"Biochem Genet"},{"key":"2215_CR49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-004-1462-8","volume":"19","author":"L T\u00fcmer","year":"2004","unstructured":"T\u00fcmer L, Ezg\u00fc FS, Hasano\u011flu A, Dalgi\u00e7 B, Bakkalo\u011flu SA, Memi\u015f L, et al. The co-existence of Fabry and celiac diseases: a case report. Pediatr Nephrol. 2004;19:679\u201381.","journal-title":"Pediatr Nephrol"},{"key":"2215_CR50","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62:1933\u201346.","journal-title":"Kidney Int"},{"key":"2215_CR51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.08091109","volume":"5","author":"U Ramaswami","year":"2010","unstructured":"Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG. Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol. 2010;5:365\u201370.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2215_CR52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int. 1978;13:223\u201335.","journal-title":"Kidney Int"},{"key":"2215_CR53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1012423924648","volume":"24","author":"A Sessa","year":"2001","unstructured":"Sessa A, Meroni M, Battini G, Maglio A, Brambilla PL, Bertella M, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis. 2001;24:66\u201370.","journal-title":"J Inherit Metab Dis"},{"key":"2215_CR54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C Tondel","year":"2008","unstructured":"Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767\u201376.","journal-title":"Am J Kidney Dis"},{"key":"2215_CR55","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","volume":"23","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23:1600\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"2215_CR56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81:122\u201338.","journal-title":"Medicine (Baltimore)"},{"key":"2215_CR57","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009;20:1132\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"2215_CR58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","volume":"429","author":"J MacDermot","year":"2001","unstructured":"MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol. 2001;429:121\u20135.","journal-title":"Eur J Pharmacol"},{"key":"2215_CR59","first-page":"36","volume":"36","author":"M Froissart","year":"2007","unstructured":"Froissart M, Benistan K, Germain DP. Functional renal investigation in Fabry disease. Presse Med. 2007;36:36\u201342.","journal-title":"Presse Med"},{"key":"2215_CR60","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med. 2006;8:539\u201348.","journal-title":"Genet Med"},{"key":"2215_CR61","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry. Clin J Am Soc Nephrol. 2010;5:2220\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2215_CR62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jbspin.2003.10.015","volume":"71","author":"C Masson","year":"2004","unstructured":"Masson C, Ciss\u00e9 I, Simon V, Insalaco P, Audran M. Fabry disease: a review. Joint Bone Spine. 2004;71:381\u20133.","journal-title":"Joint Bone Spine"},{"key":"2215_CR63","first-page":"243","volume":"81","author":"AL Mena Rodr\u00edguez","year":"2018","unstructured":"Mena Rodr\u00edguez AL, Soto Abraham MV, Valdespino V\u00e1zquez MY, de Le\u00f3n Garza B. Histopathological findings in renal biopsies in Anderson\u2013Fabry disease. Case series. Rev Med Hosp Gen Mex. 2018;81:243\u20137.","journal-title":"Rev Med Hosp Gen Mex."},{"key":"2215_CR64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/modpathol.3800344","volume":"18","author":"D Albay","year":"2005","unstructured":"Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol. 2005;18:733\u20138.","journal-title":"Mod Pathol"},{"key":"2215_CR65","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40:1668\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"2215_CR66","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57:1093\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2215_CR67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","volume":"101","author":"V Patel","year":"2015","unstructured":"Patel V, O\u2019Mahony C, Hughes D, Rahman MS, Coats C, Murphy E, et al. Clinical and genetic predictors of major cardiac events in patients with Anderson\u2013Fabry disease. Heart. 2015;101:961\u20136.","journal-title":"Heart"},{"key":"2215_CR68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","volume":"94","author":"C Kampmann","year":"2005","unstructured":"Kampmann C, Baehner FA, Whybra C, Bajbouj M, Baron K, Knuf M, et al. The right ventricle in Fabry disease. Acta Paediatr Suppl. 2005;94:15\u20138.","journal-title":"Acta Paediatr Suppl"},{"key":"2215_CR69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, St\u00f6rk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274:331\u201341.","journal-title":"J Intern Med"},{"key":"2215_CR70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","volume":"51","author":"T Takenaka","year":"2008","unstructured":"Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51:50\u20139.","journal-title":"J Cardiol"},{"key":"2215_CR71","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"26","author":"F Weidemann","year":"2005","unstructured":"Weidemann F, Breunig F, Beer M, Sandstede J, St\u00f6rk S, Voelker W, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005;26:1221\u20137.","journal-title":"Eur Heart J"},{"key":"2215_CR72","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu199","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"key":"2215_CR73","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","volume":"68","author":"TR Hsu","year":"2016","unstructured":"Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, et al. Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol. 2016;68:2554\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"2215_CR74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12968-016-0233-6","volume":"18","author":"DP Deva","year":"2016","unstructured":"Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, et al. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson\u2013Fabry disease. J Cardiovasc Magn Reson. 2016;18:14.","journal-title":"J Cardiovasc Magn Reson"},{"key":"2215_CR75","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","volume":"6","author":"RB Thompson","year":"2013","unstructured":"Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, et al. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013;6:637\u201345.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2215_CR76","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","volume":"6","author":"DM Sado","year":"2013","unstructured":"Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson\u2013Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392\u20138.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2215_CR77","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","volume":"29","author":"N Seydelmann","year":"2015","unstructured":"Seydelmann N, Wanner C, St\u00f6rk S, Ertl G, Weidemann F. Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab. 2015;29:195\u2013204.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2215_CR78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95:86\u201392.","journal-title":"Acta Paediatr"},{"key":"2215_CR79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of FD: a study on 35 European children and adolescents. Eur J Pediatr. 2003;162:767\u201372.","journal-title":"Eur J Pediatr"},{"key":"2215_CR80","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236\u201342.","journal-title":"Eur J Clin Invest."},{"key":"2215_CR81","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","volume":"30","author":"N Uceyler","year":"2014","unstructured":"Uceyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in Fabry disease. Clin J Pain. 2014;30:915\u201320.","journal-title":"Clin J Pain"},{"key":"2215_CR82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3928\/00904481-20090401-01","volume":"38","author":"J Charrow","year":"2009","unstructured":"Charrow J. A 14-year-old boy with pain in hands and feet. Pediatr Ann. 2009;38:190\u20132.","journal-title":"Pediatr Ann"},{"key":"2215_CR83","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","volume":"84","author":"MJ Hilz","year":"2000","unstructured":"Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000;84:361\u20135.","journal-title":"Pain"},{"key":"2215_CR84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pain.2009.07.025","volume":"145","author":"D Naleschinski","year":"2009","unstructured":"Naleschinski D, Arning K, Baron R. Fabry disease: pain doctors have to find the missing ones. Pain. 2009;145:10\u20131.","journal-title":"Pain"},{"key":"2215_CR85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. J Neurol Sci. 2014;344:5\u201319.","journal-title":"J Neurol Sci"},{"key":"2215_CR86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clineuro.2006.12.006","volume":"109","author":"S Saip","year":"2007","unstructured":"Saip S, Uluduz D, Erkol G. Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg. 2007;109:361\u20133.","journal-title":"Clin Neurol Neurosurg"},{"key":"2215_CR87","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0190-9622(87)70274-6","volume":"17","author":"WH Kang","year":"1987","unstructured":"Kang WH, Chun SI, Lee S. Generalized anhidrosis associated with Fabry\u2019s disease. J Am Acad Dermatol. 1987;17:883\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"2215_CR88","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, et al. Fabry disease and the skin: data from FOS, the Fabry Outcome Survey. Br J Dermatol. 2007;157:331\u20137.","journal-title":"Br J Dermatol"},{"key":"2215_CR89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2377-8-41","volume":"8","author":"SN Gupta","year":"2008","unstructured":"Gupta SN, Ries M, Murray GJ, Quirk JM, Brady RO, Lidicker JR, et al. Skin-impedance in Fabry disease: a prospective, controlled, non-randomized clinical study. BMC Neurol. 2008;8:41.","journal-title":"BMC Neurol"},{"key":"2215_CR90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1529-8027.2009.00227.x","volume":"14","author":"AT M\u00f8ller","year":"2009","unstructured":"M\u00f8ller AT, Bach FW, Feldt-Rasmussen U, Rasmussen AK, Hasholt L, Sommer C, et al. Autonomic skin responses in females with Fabry disease. J Peripher Nerv Syst. 2009;14:159\u201364.","journal-title":"J Peripher Nerv Syst"},{"key":"2215_CR91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.autneu.2010.01.008","volume":"155","author":"PH Ellaway","year":"2010","unstructured":"Ellaway PH, Kuppuswamy A, Nicotra A, Mathias CJ. Sweat production and the sympathetic skin response: improving the clinical assessment of autonomic function. Auton Neurosci. 2010;155:109\u201314.","journal-title":"Auton Neurosci"},{"key":"2215_CR92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","volume":"3","author":"DP Germain","year":"2002","unstructured":"Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet. 2002;3:10.","journal-title":"BMC Med Genet"},{"key":"2215_CR93","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.anl.2009.01.001","volume":"36","author":"Y Sakurai","year":"2009","unstructured":"Sakurai Y, Kojima H, Shiwa M, Ohashi T, Eto Y, Moriyama H. The hearing status in 12 female and 15 male Japanese Fabry patients. Auris Nasus Larynx. 2009;36:627\u201332.","journal-title":"Auris Nasus Larynx"},{"key":"2215_CR94","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1651-2227.2003.tb00219.x","volume":"92","author":"G Conti","year":"2003","unstructured":"Conti G, Sergi B. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr Suppl. 2003;92:33\u20137.","journal-title":"Acta Paediatr Suppl"},{"key":"2215_CR95","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/AUD.0000000000001030","volume":"42","author":"E Kiykim","year":"2021","unstructured":"Kiykim E, Kaya M, Dincer MT, Bakir A, Alagoz S, Aktuglu Zeybek A, et al. Reflex decay test can reveal ear involvement in Fabry disease. Ear Hear. 2021;42:1351\u20137.","journal-title":"Ear Hear"},{"key":"2215_CR96","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5:1447\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2215_CR97","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.2174\/13816128113199990347","volume":"19","author":"P Buda","year":"2013","unstructured":"Buda P, Ksi\u0105\u017cyk J, Tylki-Szymanska A. Gastroenterological complications of Anderson\u2013Fabry disease. Curr Pharm Des. 2013;19:6009\u201313.","journal-title":"Curr Pharm Des"},{"key":"2215_CR98","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","volume":"46","author":"E Kolodny","year":"2015","unstructured":"Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015;46:302\u201313.","journal-title":"Stroke"},{"key":"2215_CR99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jocn.2019.03.064","volume":"65","author":"S Sheng","year":"2019","unstructured":"Sheng S, Wu L, Nalleballe K, Sharma R, Brown A, Ranabothu S, et al. Fabry\u2019s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci. 2019;65:83\u20136.","journal-title":"J Clin Neurosci"},{"key":"2215_CR100","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/STROKEAHA.116.016083","volume":"48","author":"S Lanthier","year":"2017","unstructured":"Lanthier S, Saposnik G, Lebovic G. Prevalence of Fabry disease and outcomes in young Canadian patients with cryptogenic ischemic cerebrovascular events. Stroke. 2017;48:1766\u201372.","journal-title":"Stroke"},{"key":"2215_CR101","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000322153","volume":"31","author":"A Rolfs","year":"2011","unstructured":"Rolfs A, Martus P, Heuschmann PU. Protocol and methodology of the Stroke in Young Fabry patients (sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18\u201355 years. Cerebrovasc Dis. 2011;31:253\u201362.","journal-title":"Cerebrovasc Dis"},{"key":"2215_CR102","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000002673","volume":"86","author":"NS Rost","year":"2016","unstructured":"Rost NS, Cloonan L, Kanakis AS, Fitzpatrick KM, Azzariti DR, Clarke V, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology. 2016;86:1880\u20136.","journal-title":"Neurology"},{"key":"2215_CR103","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","volume":"38","author":"A Fellgiebel","year":"2014","unstructured":"Fellgiebel A, Gartenschl\u00e4ger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis. 2014;38:448\u201356.","journal-title":"Cerebrovasc Dis"},{"key":"2215_CR104","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3174\/ajnr.A5069","volume":"38","author":"R Manara","year":"2017","unstructured":"Manara R, Carlier RY, Righetto S, Citton V, Locatelli G, Colas F, et al. Basilar artery changes in Fabry disease. Am J Neuroradiol. 2017;38:531\u20136.","journal-title":"Am J Neuroradiol"},{"key":"2215_CR105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009;40:788\u201394.","journal-title":"Stroke"},{"key":"2215_CR106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","volume":"27","author":"L Jardim","year":"2004","unstructured":"Jardim L, Vedolin L, Schwartz IV, Burin MG, Cecchin C, Kalakun L, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. 2004;27:229\u201340.","journal-title":"J Inherit Metab Dis"},{"key":"2215_CR107","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1212\/01.wnl.0000173030.70057.eb","volume":"65","author":"A Fellgiebel","year":"2005","unstructured":"Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65:600\u20132.","journal-title":"Neurology"},{"key":"2215_CR108","first-page":"1096","volume":"24","author":"DF Moore","year":"2003","unstructured":"Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003;24:1096\u2013101.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2215_CR109","first-page":"916","volume":"24","author":"J Takanashi","year":"2003","unstructured":"Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol. 2003;24:916\u201321.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2215_CR110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","volume":"255","author":"AP Burlina","year":"2008","unstructured":"Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol. 2008;255:738\u201344.","journal-title":"J Neurol"},{"key":"2215_CR111","doi-asserted-by":"crossref","first-page":"7758","DOI":"10.18632\/oncotarget.23970","volume":"9","author":"P Colomba","year":"2018","unstructured":"Colomba P, Zizzo C, Alessandro R, Cammarata G, Scalia S, Giordano A, et al. Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs. Oncotarget. 2018;9:7758\u201362.","journal-title":"Oncotarget"},{"key":"2215_CR112","first-page":"1","volume":"4","author":"A Burlina","year":"2016","unstructured":"Burlina A, Politei J. The central nervous system involvement in Fabry disease: a review. J Inborn Err Metab Screening. 2016;4:1\u20137.","journal-title":"J Inborn Err Metab Screening"},{"key":"2215_CR113","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1148\/radiol.2231010707","volume":"223","author":"JC Bot","year":"2002","unstructured":"Bot JC, Barkhof F, Lycklama \u00e0 Nijeholt G, van Schaardenburg D, Voskuyl AE, Ader HJ, et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology. 2002;223:46\u201356.","journal-title":"Radiology"},{"key":"2215_CR114","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","volume":"53","author":"N Samiy","year":"2008","unstructured":"Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol. 2008;53:416\u201323.","journal-title":"Surv Ophthalmol"},{"key":"2215_CR115","doi-asserted-by":"crossref","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","volume":"10","author":"S Pitz","year":"2015","unstructured":"Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLOS ONE. 2015;10:e0120814.","journal-title":"PLOS ONE."},{"key":"2215_CR116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1442-9071.2005.00990.x","volume":"33","author":"TT Nguyen","year":"2005","unstructured":"Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry disease treatment centre. Clin Exp Ophthalmol. 2005;33:164\u20138.","journal-title":"Clin Exp Ophthalmol"},{"key":"2215_CR117","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry\u2019s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91:210\u20134.","journal-title":"Br J Ophthalmol"},{"key":"2215_CR118","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00417-008-0962-9","volume":"247","author":"K Falke","year":"2009","unstructured":"Falke K, Buttner A, Schittkowski M, Stachs O, Kraak R, Zhivov A, et al. The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. Graefes Arch Clin Exp Ophthalmol. 2009;247:523\u201334.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2215_CR119","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jmg.38.9.629","volume":"38","author":"P Boutouyrie","year":"2001","unstructured":"Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Noninvasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet. 2001;38:629\u201331.","journal-title":"J Med Genet"},{"key":"2215_CR120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","volume":"24","author":"C Orssaud","year":"2003","unstructured":"Orssaud C, Dufier J, Germain DP. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet. 2003;24:129\u201339.","journal-title":"Ophthalmic Genet"},{"key":"2215_CR121","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10792-017-0495-5","volume":"38","author":"MG Ersoz","year":"2018","unstructured":"Ersoz MG, Ture G. Cilioretinal artery occlusion and anterior ischemic optic neuropathy as the initial presentation in a child female carrier of Fabry disease. Int Ophthalmol. 2018;38:771\u20133.","journal-title":"Int Ophthalmol"},{"key":"2215_CR122","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bjo.2009.176651","volume":"94","author":"LE Allen","year":"2010","unstructured":"Allen LE, Cosgrave EM, Kersey JP, Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br J Ophthalmol. 2010;94:1602\u20135.","journal-title":"Br J Ophthalmol"},{"key":"2215_CR123","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamaophthalmol.2013.2374","volume":"131","author":"DS Rudich","year":"2013","unstructured":"Rudich DS, Curcio CA, Wasserstein M, Brodie SE. Inner macular hyperreflectivity demonstrated by optical coherence tomography in niemann-pick disease. JAMA Ophthalmol. 2013;131:1244\u20136.","journal-title":"JAMA Ophthalmol"},{"key":"2215_CR124","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archopht.122.9.1395","volume":"122","author":"EM Shrier","year":"2004","unstructured":"Shrier EM, Barr CC, Grabowski GA. Vitreous opacities and retinal vascular abnormalities in Gaucher disease. Arch Ophthalmol. 2004;122:1395\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2215_CR125","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2133.2012.10742.x","volume":"166","author":"A Zampetti","year":"2012","unstructured":"Zampetti A, Orteu CH, Antuzzi D, Bongiorno MR, Manco S, Gnarra M, et al. Angiokeratoma: decision-making aid for the diagnosis of Fabry disease. Br J Dermatol. 2012;166:712\u201320.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"2215_CR126","first-page":"45","volume":"161","author":"S Dhoat","year":"2009","unstructured":"Dhoat S, Orteu CH, Navarro C, Lidove O, Jamsen T, Clarke J. Patients with Fabry disease with cutaneous vascular lesions have higher disease severity scores and more multisystem involvement: data from 1354 patients registered on FOS, the Fabry outcome survey. Br J Dermatol. 2009;161(Suppl 1):45.","journal-title":"Br J Dermatol"},{"key":"2215_CR127","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1525-1470.1995.tb00161.x","volume":"12","author":"ED Shelley","year":"1995","unstructured":"Shelley ED, Shelley WB, Kurczynski TW. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol. 1995;12:215\u20139.","journal-title":"Pediatr Dermatol"},{"key":"2215_CR128","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.ejhg.5201798","volume":"15","author":"J Cox-Brinkman","year":"2007","unstructured":"Cox-Brinkman J, Vedder A, Hollak C, Richfield L, Mehta A, Orteu K, et al. Three-dimensional face shape in Fabry disease. Eur J Hum Genet. 2007;15:535\u201342.","journal-title":"Eur J Hum Genet"},{"key":"2215_CR129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00128071-200304030-00005","volume":"4","author":"M Mohrenschlager","year":"2003","unstructured":"Mohrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol. 2003;4:189\u201396.","journal-title":"Am J Clin Dermatol"},{"key":"2215_CR130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00401-005-0026-8","volume":"111","author":"C Navarro","year":"2006","unstructured":"Navarro C, Teijeira S, Dominguez C, Fernandez JM, Rivas E, Fachal C, et al. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. Acta Neuropathol. 2006;111:178\u201385.","journal-title":"Acta Neuropathol"},{"issue":"4 Suppl","key":"2215_CR131","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jpeds.2009.07.003","volume":"155","author":"AM Martins","year":"2009","unstructured":"Martins AM, D\u2019Almeida V, Kyosen SO, Takata ET, Delgado AG, Gon\u00e7alves AM, et al. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr. 2009;155(4 Suppl):S19\u201331.","journal-title":"J Pediatr."},{"key":"2215_CR132","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1046\/j.1523-1755.2003.00196.x","volume":"64","author":"JP Grunfeld","year":"2003","unstructured":"Grunfeld JP. How to improve the early diagnosis of Fabry\u2019s disease? Kidney Int. 2003;64:1136\u20137.","journal-title":"Kidney Int"},{"key":"2215_CR133","first-page":"225","volume-title":"Fabry disease","author":"G David","year":"2010","unstructured":"David G, Warnock DG, Valbuena C, West M, Oliveira JP. Renal manifestations of Fabry disease. In: Elstein D, Altarescu G, Beck M, editors. Fabry disease. Springer; 2010. p. 225."},{"key":"2215_CR134","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","volume":"22","author":"DA Laney","year":"2013","unstructured":"Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, et al. Fabry disease practice guidelines: recommendations of the National Society of genetic counselors. J Genet Couns. 2013;22:555\u201364.","journal-title":"J Genet Couns"},{"key":"2215_CR135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rce.2018.03.018","volume":"218","author":"RM L\u00f3pez","year":"2018","unstructured":"L\u00f3pez RM. Treatment in Fabry disease. Rev Clin Esp. 2018;218:489\u201395.","journal-title":"Rev Clin Esp"},{"key":"2215_CR136","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","volume":"177","author":"BE Smid","year":"2014","unstructured":"Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177:400\u20138.","journal-title":"Int J Cardiol"},{"key":"2215_CR137","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08035320510031045","volume":"94","author":"E Schaefer","year":"2005","unstructured":"Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94:87\u201392.","journal-title":"Acta Paediatr Suppl"},{"key":"2215_CR138","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000500570","volume":"143","author":"MC Braga","year":"2019","unstructured":"Braga MC, Fonseca FLA, Marins MM, Gomes CP, Bacci MR, Martins AM, et al. Evaluation of Beta 2-microglobulin, cystatin C, and lipocalin-2 as renal biomarkers for patients with Fabry disease. Nephron. 2019;143:217\u201327.","journal-title":"Nephron"},{"key":"2215_CR139","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rce.2017.06.007","volume":"218","author":"S Olivera-Gonz\u00e1lez","year":"2018","unstructured":"Olivera-Gonz\u00e1lez S, Josa-Laorden C, Torralba-Cabeza MA. The pathophysiology of Fabry disease. Rev Clin Esp. 2018;218:22\u20138.","journal-title":"Rev Clin Esp"},{"key":"2215_CR140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","volume":"15","author":"S Waldek","year":"2014","unstructured":"Waldek S, Feriozzi S. Fabry nephropaty: a review\u2014how can weoptimize the management of Fabry nephropaty. BMC Nephrol. 2014;15:72\u201384.","journal-title":"BMC Nephrol"},{"key":"2215_CR141","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/jcm10081664","volume":"10","author":"C Carnicer-C\u00e1ceres","year":"2021","unstructured":"Carnicer-C\u00e1ceres C, Arranz-Amo JA, Cea-Arestin C, Camprodon-Gomez M, Moreno-Martinez D, Lucas-Del-Pozo S, et al. Biomarkers in Fabry disease implications for clinical diagnosis and follow-up. J Clin Med. 2021;10:1664.","journal-title":"J Clin Med"},{"key":"2215_CR142","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"180","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;180:741\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"2215_CR143","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2215_CR144","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22:843\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"2215_CR145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","volume":"86","author":"L Shu","year":"2014","unstructured":"Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, et al. Establishing 3-nitrotyrosine as a biomarkerfor the vasculopathy of Fabry disease. Kidney Int. 2014;86:58\u201366.","journal-title":"Kidney Int"},{"key":"2215_CR146","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12967-016-1049-8","volume":"13","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Canzonieri R, Schiel A, Costales-Collaguazo C, Politei J, Stern A, et al. Increased urinary CD80 excretionand podocyturia in Fabry disease. J Transl Med. 2016;13:289.","journal-title":"J Transl Med"},{"key":"2215_CR147","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","volume":"31","author":"N Brakch","year":"2010","unstructured":"Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31:67\u201376.","journal-title":"Eur Heart J"},{"key":"2215_CR148","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1014545521753","volume":"11","author":"RL Bennett","year":"2002","unstructured":"Bennett RL, Hart KA, O\u2019Rourke E, Barranger JA, Johnson J, MacDermot KD, et al. Fabry disease in genetic counseling practice: recommendations of the National Society of genetic counselors. J Genet Couns. 2002;11:121\u201346.","journal-title":"J Genet Couns"},{"key":"2215_CR149","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","volume":"17","author":"DA Laney","year":"2008","unstructured":"Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of family history. J Genet Couns. 2008;17:79\u201383.","journal-title":"J Genet Couns"},{"key":"2215_CR150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51:1\u20139.","journal-title":"J Med Genet"},{"key":"2215_CR151","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","volume":"39","author":"D Matern","year":"2015","unstructured":"Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S. Newborn screening for lysosomal storage disorders. Semin Perinatol. 2015;39:206\u201316.","journal-title":"Semin Perinatol"},{"key":"2215_CR152","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/8904_2014_342","volume":"17","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Cassiman D, Houge G, Janssen MC, Lachmann RH, Linthorst GE, et al. Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep. 2014;17:83\u201390.","journal-title":"JIMD Rep"},{"key":"2215_CR153","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/17530059.2013.846322","volume":"7","author":"AS Thomas","year":"2013","unstructured":"Thomas AS, Mehta AB. Difficulties and barriers in diagnosing FD: what can be learnt from the literature? Expert Opin Med Diagn. 2013;7:589\u201399.","journal-title":"Expert Opin Med Diagn"},{"key":"2215_CR154","doi-asserted-by":"crossref","first-page":"e55565","DOI":"10.1371\/journal.pone.0055565","volume":"8","author":"M Lenders","year":"2013","unstructured":"Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A, et al. Multifocal white matter lesions associated with the D313Y mutation of the alpha-galactosidase A gene. PLOS ONE. 2013;8:e55565.","journal-title":"PLOS ONE."},{"key":"2215_CR155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2012_154","volume":"7","author":"M Niemann","year":"2013","unstructured":"Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, et al. Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry disease. JIMD Rep. 2013;7:99\u2013102.","journal-title":"JIMD Rep"},{"key":"2215_CR156","first-page":"81","volume":"3","author":"R Tolouian","year":"2010","unstructured":"Tolouian R, Salameh H. Treat the patient not the lab value. NDT Plus. 2010;3:81\u20133.","journal-title":"NDT Plus"},{"key":"2215_CR157","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","volume":"88","author":"BE Smid","year":"2015","unstructured":"Smid BE, Hollak CE, Poorthuis BJ, van den Bergh Weerman MA, Florquin S, Kok WE, et al. Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance. Clin Genet. 2015;88:161\u20136.","journal-title":"Clin Genet"},{"key":"2215_CR158","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1515\/jpem-2020-0056","volume":"33","author":"H Onay","year":"2020","unstructured":"Onay H, Bolat H, K\u0131l\u0131\u00e7 Y\u0131ld\u0131r\u0131m G, Kose E, Ucar SK, Asikoval\u0131 S, et al. Analysis of the alpha galactosidase gene: mutation profile and description of two novel mutations with extensive literature review in Turkish population. J Pediatr Endocrinol Metab. 2020;33:1245\u201350.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2215_CR159","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2019","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2019;5:407\u201313.","journal-title":"Kidney Int Rep"},{"key":"2215_CR160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003;13:305\u201313.","journal-title":"Glycobiology"},{"key":"2215_CR161","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","volume":"25","author":"DG Warnock","year":"2014","unstructured":"Warnock DG, Mauer M. Fabry disease: dose matters. J Am Soc Nephrol. 2014;25:653\u20135.","journal-title":"J Am Soc Nephrol"},{"key":"2215_CR162","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","volume":"4","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther. 2004;4:1167\u201376.","journal-title":"Expert Opin Biol Ther"},{"key":"2215_CR163","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","volume":"107","author":"A Pisani","year":"2012","unstructured":"Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab. 2012;107:267\u201375.","journal-title":"Mol Genet Metab"},{"key":"2215_CR164","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet. 2009;374:1986\u201396.","journal-title":"Lancet"},{"key":"2215_CR165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153\u20138.","journal-title":"Heart"},{"key":"2215_CR166","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40620-020-00721-4","volume":"34","author":"S Feriozzi","year":"2021","unstructured":"Feriozzi S, Hughes DA. New drugs for the treatment of Anderson\u2013Fabry disease. J Nephrol. 2021;34:221\u201330.","journal-title":"J Nephrol"},{"key":"2215_CR167","doi-asserted-by":"crossref","first-page":"912","DOI":"10.12688\/f1000research.8010.1","volume":"5","author":"Q Chen","year":"2016","unstructured":"Chen Q, Davis KR. The potential of plants as a system for the development and production of human biologics. F1000Res. 2016;5:912.","journal-title":"F1000Res."},{"key":"2215_CR168","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, et al. Characterization of a chemically modified plant cell culture expressed human alpha-galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114:259\u201367.","journal-title":"Mol Genet Metab"},{"key":"2215_CR169","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial. J Inherit Metab Dis. 2019;42:534\u201344.","journal-title":"J Inherit Metab Dis"},{"key":"2215_CR170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, et al. Fabry pediatric expert panel. The management and treatment of children with Fabry disease: A United States-based perspective. Mol Genet Metab. 2016;117:104\u201313.","journal-title":"Mol Genet Metab."},{"key":"2215_CR171","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81:635\u201345.","journal-title":"Drugs"},{"key":"2215_CR172","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","volume":"4","author":"O Motabar","year":"2010","unstructured":"Motabar O, Sidransky E, Goldin E, Zheng W. Fabry disease\u2013current treatment and new drug development. Curr Chem Genomics. 2010;4:50\u20136.","journal-title":"Curr Chem Genomics"},{"key":"2215_CR173","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545\u201355.","journal-title":"N Engl J Med"},{"key":"2215_CR174","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54:288\u201396.","journal-title":"J Med Genet"},{"key":"2215_CR175","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","volume":"28","author":"E Riccio","year":"2020","unstructured":"Riccio E, Zanfardino M, Ferreri L, Santoro C, Cocozza S, Capuano I, et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Eur J Hum Genet. 2020;28:1662\u20138.","journal-title":"Eur J Hum Genet"},{"key":"2215_CR176","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79:543\u201354.","journal-title":"Drugs"},{"key":"2215_CR177","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","volume":"27","author":"RWD Welford","year":"2018","unstructured":"Welford RWD, M\u00fchlemann A, Garzotti M, Rickert V, Groenen PMA, Morand O, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018;27:3392\u2013403.","journal-title":"Hum Mol Genet"},{"key":"2215_CR178","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","volume":"43","author":"SJ van der Veen","year":"2020","unstructured":"van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020;43:908\u201321.","journal-title":"J Inherit Metab Dis"},{"key":"2215_CR179","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2021.07.006","volume":"134","author":"JM Domm","year":"2021","unstructured":"Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing. Mol Genet Metab. 2021;134:117\u201331.","journal-title":"Mol Genet Metab"},{"key":"2215_CR180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539\u201348.","journal-title":"Genet Med"},{"key":"2215_CR181","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"key":"2215_CR182","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/8904_2018_141","volume":"45","author":"P Fern\u00e1ndez","year":"2019","unstructured":"Fern\u00e1ndez P, Fern\u00e1ndez SO, Gonzalez JGM, Fern\u00e1ndez T, Fern\u00e1ndez CC, Fern\u00e1ndez SP. Enzyme replacement therapy in pregnant women with Fabry disease: a case series. JIMD Rep. 2019;45:77\u201381.","journal-title":"JIMD Rep"},{"key":"2215_CR183","first-page":"406","volume":"9","author":"E Senocak Tasci","year":"2015","unstructured":"Senocak Tasci E, Bicik Z. Safe and successful treatment with agalsidase beta during pregnancy in Fabry disease. Iran J Kidney Dis. 2015;9:406\u20138.","journal-title":"Iran J Kidney Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02215-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:02:47Z","timestamp":1726750967000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02215-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":183,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2215"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02215-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}